Moffitt at SITC
Moffitt Cancer Center’s research focuses on cutting-edge discoveries that can be rapidly translated into improved diagnostic, preventive and therapeutic advances. As pioneers of immunotherapy as a groundbreaking cancer treatment, we are excited to participate in the conference. The studies our scientists are presenting explore many advances in areas like CAR T and TIL therapy and cover many cancer types like melanoma, sarcoma and bladder cancer.
Join Moffitt CEO and SITC President Patrick Hwu MD at the Society for Immunotherapy of Cancer’s 36th Annual Meeting. Dr. Hwu will give the welcome address and introduce the keynote session on Friday, November 12, and lead the business meeting and presidential session on Saturday, November 13.
Don’t forget to stop by and meet our Moffitt team in Booth #705.
Check back for more highlights from the 2021 meeting.
Expanded TIL Therapy Shows Promise for Sarcoma Patients
Clinical trials show promise for AYA population
Identifying Enhanced Response to Immunotherapy in Melanoma
New studies show gender and cancer origin can affect how well patients respond to treatment
Can Tumor Mutations Cause Resistance to Cellular Immunotherapy?
Study shows certain alterations can indicate poor outcomes for lymphoma patients receiving CAR T-cell therapy
For additional information on Moffitt’s research presented at SITC please reach out to:
Kim Polacek, APR, CPRC
Senior PR Account Coordinator